Review of Pipeline Drugs and Therapeutics for Genetic Muscular Dystrophies Presented in New Report

Published Date : May 29, 2017

ALBANY, New York, May 29, 2017- has featured a new market study, titled “Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017,” to its expanding database. The report is a professional study for review of pipeline drugs and therapeutics for genetic muscular dystrophies. The report looks into vital market indicators and growth trends for a know-how of therapeutics and pipeline drugs for indications discussed herein. 

Becker Muscular Dystrophy (BMD) is a condition with symptoms such as difficulty in running, hopping, toe walking, cognitive problems, frequent falls, and breathing problems. Duchenne Muscular Dystrophy (DMD) is a condition which is characterized by muscle weakness.

The size of pipeline drugs vary greatly from six in BMD and to 108 in DMD cites the report. Of the major pipeline drugs for DMD, majority target dystrophin, which is the causative gene for the condition. However, a number of pipeline drugs work on a number of other molecular targets such as utrophin and nuclear factor kappa B. 

The report presents answers for several questions that are important with respect to pipeline review of muscular dystrophy indications. This includes examining the most active companies for therapeutics and pipeline drugs for genetic muscular dystrophies, involvement of universities and research institutions over pharmaceutical companies for these indications, and R&D milestones attained for genetic disorder therapeutics. 

For Sample Copy, click here: 

The report is a useful tool for its many offerings. It allows understanding the overall pipeline for genetic muscular dystrophies and a glance into products for therapeutic development for each indication. Furthermore, it assesses the granular details of products under development and an updated overview of pipeline program for each indication. The report also analyzes the companies, research institutions, and universities currently involved in the pipeline and therapeutics for these indications and products fielded by each of them. Last but not the least, included in this report is a discussion on pipeline drugs in terms of molecule type, action mechanism, molecular target, and route of administration. 

The report has been collated employing standard analytical tools and research methodologies after a primary and secondary research phase. The secondary research phase involved data collection from a multitude of printable and non-printable sources such as government agencies, search engines, industry portals, trade associations, white papers, and through paid databases. 

The key companies involved in the pipeline for BMD include Cardeo Therapeutics Inc., PTC Therapeutics Inc., Sarepta Therapeutics, Milo Biotechnology LLC, and ReveraGen BioPharma Inc. Some major companies involved in pipeline for DMD include Acceleron Pharma Inc., Asklepios BioPharmaceutical Inc., Bristol-Myers Squibb Company, Cardero Therapeutics Inc., CRISPR Therapeutics, Debiopharm International SA, Eloxx Pharmaceuticals Ltd., Galapagos NV, GTx Inc., Idera Pharmaceuticals Inc., La Jolla Pharmaceuticals Company, Marina Biotech Inc.,  Milo Biotechnology LLC, Mitochon Pharmaceuticals Inc., NicOx, Nobelpharma Co. Ltd, Pfizer Inc., Prothelia Inc., ReveraGen BioPharma Inc., Sarepta Therapeutics Inc., and Taiho Pharmaceuticals Co. Ltd. among others. 

To order report Call Toll Free: 866-997-4948 or send an email on